02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
09 Jan - 
Adaptimmune confirms GSK Nomination of Second Adaptimmu..
05 Dec - 
Adaptimmune Announces Initiation of Myxoid/Round Cell L..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

P. Schoenfeld Asset Management LLP : Form 8.3 - Booker Group plc

26/05/2017 15:00:03
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: P. Schoenfeld Asset Management LLP (b) Owner or..

Alliance Trust PLC : Net Asset Value(s)

26/05/2017 13:45:51
ALLIANCE TRUST PLC                                    At the close of business on Thursday 25 May 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 733.6p -       including income, 743.3p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding income..

Statement re Notification of Transactions of Directors - GRANT OF SHARE AWARDS

26/05/2017 10:15:05
Intermediate Capital Group plc 25 May 2017 Notification of Transactions of Directors GRANT OF SHARE AWARDS In accordance with the UK Financial Services Authority Disclosure and Transparency Rule 3.1.4, the Company wishes to announce that on 25 May 2017 PLC Equity Awards and Deferred Share Awards under the Intermediate Capital Group Omnibus Plan were granted to the Directors named below over ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label

Related stock quotes

Glaxosmithkline PLC ORD .. 1,644.59 1.6% Stock price increasing
GlaxoSmithKline PLC 42.67 0.2% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
28 May 2017 13:30:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170517.1 - EUROWEB4 - 2017-05-28 14:30:20 - 2017-05-28 13:30:20 - 1000 - Website: OKAY